• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.

作者信息

Kosugi Yusuke, Kaku Yu, Hinay Alfredo A, Guo Ziyi, Uriu Keiya, Kihara Minoru, Saito Fumitake, Uwamino Yoshifumi, Kuramochi Jin, Shirakawa Kotaro, Takaori-Kondo Akifumi, Sato Kei

机构信息

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

出版信息

Lancet Infect Dis. 2024 Mar;24(3):e147-e148. doi: 10.1016/S1473-3099(23)00784-3. Epub 2024 Jan 8.

DOI:10.1016/S1473-3099(23)00784-3
PMID:38211599
Abstract
摘要

相似文献

1
Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.XBB.1.5单价疫苗在未感染过新冠病毒及感染过XBB的个体中诱导产生的针对新冠病毒奥密克戎亚变体的抗病毒体液免疫。
Lancet Infect Dis. 2024 Mar;24(3):e147-e148. doi: 10.1016/S1473-3099(23)00784-3. Epub 2024 Jan 8.
2
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.XBB.1.5 刺突蛋白 COVID-19 疫苗诱导针对 EG.5.1 和新兴 XBB 变异株的广泛中和及细胞免疫应答。
Sci Rep. 2023 Nov 6;13(1):19176. doi: 10.1038/s41598-023-46025-y.
3
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.儿童感染 SARS-CoV-2 或接种疫苗后对奥密克戎 BQ.1、BQ.1.1 和 XBB.1 变异株的中和作用。
Nat Commun. 2023 Dec 1;14(1):7952. doi: 10.1038/s41467-023-43152-y.
4
Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.基于新型化学发光、病毒介导细胞病变法评估 BA.5 突破感染和三剂疫苗接种对奥密克戎亚变体的中和活性。
Microbiol Spectr. 2023 Aug 17;11(4):e0066023. doi: 10.1128/spectrum.00660-23. Epub 2023 Jun 13.
5
Impact of Imprinted Immunity Induced by mRNA Vaccination in an Experimental Animal Model.mRNA 疫苗接种诱导的印迹免疫对实验动物模型的影响。
J Infect Dis. 2023 Oct 18;228(8):1060-1065. doi: 10.1093/infdis/jiad230.
6
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.严重急性呼吸综合征冠状病毒2型奥密克戎XBB亚变体在老年人群中表现出增强的融合性和显著的免疫逃逸能力，但对泛冠状病毒融合抑制剂高度敏感。
J Med Virol. 2023 Mar;95(3):e28641. doi: 10.1002/jmv.28641.
7
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.令人担忧的 SARS-CoV-2 BQ 和 XBB 亚型不断出现的抗体逃逸特性。
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
8
Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.在未感染和既往感染人群中，BNT162b2 加强针接种对 SARS-CoV-2 奥密克戎 BA.2、BA.3、BA.4 和 BA.5 亚变异株的刺突结合抗体的影响。
Vaccine. 2023 Jan 23;41(4):879-882. doi: 10.1016/j.vaccine.2022.12.049. Epub 2022 Dec 24.
9
Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.接种含BA.4/5的二价mRNA疫苗个体的血清对奥密克戎亚变体BN.1和XBB.1.5的中和活性较低。
Immune Netw. 2023 Nov 13;23(6):e43. doi: 10.4110/in.2023.23.e43. eCollection 2023 Dec.
10
Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.同源或异源加强针对奥密克戎 BA.5.2.48、BF.7.14、XBB.1 亚系的中和作用较低。
J Med Virol. 2023 Dec;95(12):e29306. doi: 10.1002/jmv.29306.

引用本文的文献

1
Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024.2024年5月通过对苏格兰初级和二级医疗保健机构进行随机抽样来评估人群对新冠病毒的免疫力。
EBioMedicine. 2025 Jun;116:105760. doi: 10.1016/j.ebiom.2025.105760. Epub 2025 May 16.
2
The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells.XBB.1.5 mRNA加强疫苗不会显著增加XBB.1.5单反应性T细胞的百分比。
Front Immunol. 2025 Mar 12;16:1513175. doi: 10.3389/fimmu.2025.1513175. eCollection 2025.
3
Neutralizing antibody responses to three XBB protein vaccines in older adults.
老年人对三种XBB蛋白疫苗的中和抗体反应。
Signal Transduct Target Ther. 2025 Feb 3;10(1):48. doi: 10.1038/s41392-025-02132-y.
4
Strategies Used by SARS-CoV-2 to Evade the Innate Immune System in an Evolutionary Perspective.从进化角度看，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）逃避天然免疫系统的策略
Pathogens. 2024 Dec 17;13(12):1117. doi: 10.3390/pathogens13121117.
5
Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.人类和仓鼠血清在鉴定 SARS-CoV-2 变体（包括 JN.1）中的抗原漂移方面具有良好的相关性。
J Virol. 2024 Nov 19;98(11):e0094824. doi: 10.1128/jvi.00948-24. Epub 2024 Oct 4.
6
Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.XBB.1.5 mRNA 疫苗加强针接种 6 个月后仍保持强劲的 SARS-CoV-2 中和抗体。
Cell Rep Med. 2024 Sep 17;5(9):101701. doi: 10.1016/j.xcrm.2024.101701. Epub 2024 Aug 28.
7
Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.使用仓鼠血清的抗原图谱分析确定了在人类XBB.1.5加强针血清中观察到的SARS-CoV-2 JN.1逃逸情况。
bioRxiv. 2024 Apr 6:2024.04.05.588359. doi: 10.1101/2024.04.05.588359.
8
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.XBB.1.5 单价 mRNA 疫苗加强针可诱导针对 XBB 亚谱系和 JN.1 的强大中和抗体。
Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. doi: 10.1016/j.chom.2024.01.014. Epub 2024 Feb 19.
9
Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines.对与新冠病毒变异株适配mRNA疫苗相关常见误解的回应。
Vaccines (Basel). 2024 Jan 6;12(1):57. doi: 10.3390/vaccines12010057.